Elsa Abranches | Chief Scientific Officer
ViSync Technologies
Elsa Abranches holds a degree in Chemical Engineering and a Ph.D. in Stem Cell Biotechnology, from the Technical University of Lisbon, Portugal. Elsa has over 20 years of experience in stem cell biotechnology, standardization and Advanced Therapies regulation areas, ranging from applied research through to manufacturing and regulatory compliance of stem cell-derived products. She has held roles at AstraZeneca and at the UK Medicines and Healthcare products Regulatory Agency (MHRA). She has also contributed to numerous collaborative projects with academia, industry and regulatory bodies and has served on several national and international committees supporting regulatory compliance in Advanced Therapy Medicinal Products (ATMPs). Currently, Elsa is Chief Scientific Officer at ViSync Technologies and the regional treasurer of the European Committee of the International Society for Cell & Gene Therapy (ISCT).
Appearances:
Festival of Biologics Day 2 @ 11:45
Roundtables
Dry State, High Stakes: Formulating the Future of Biologics
Festival of Biologics Day 3 @ 17:10
Powder Power: Transforming Biologic Modalities with Dry Formulations
- Biologic therapies are transforming medicine, but their full potential is often limited by challenges in stability, storage, and delivery (especially for complex modalities like cell and gene therapies).
- Dry powder formulations offer a promising solution, enabling enhanced stability, simplified logistics, and new routes of administration, including needle-free options like nasal delivery, that can improve patient access and compliance.
- By rethinking formulation from the ground up, we can unlock new possibilities for advanced therapies, accelerating innovation and expanding the reach of life-changing treatments.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events